AGRX - Agile Therapeutics: Another Quarter Of Progress And Another Opportunity To Buy

• Agile Therapeutics recently reported their Q2 earnings with a beat on EPS and a miss on revenue. The company’s flagship product, Twirla, is already starting to display impressive growth trends.
• The market had a difficult time determining which direction it wants to take the share price, which has provided me an opportunity to add to my AGRX position.
• I will review the company's Q2 earnings and will highlight some key metrics for investors to follow as Twirla moves deeper into commercialization.
• I take a look at AGRX’s current valuation and will discuss how it influences the way I manage my position going forward.

For further details see: